Alzinova has recruited half of the patients for the ongoing Phase 1b study of the vaccine candidate ALZ-101
Alzinova AB (publ) (”Alzinova” or “the Company”), announces today that the Phase 1b study for the unique vaccine candidate ALZ-101 against Alzheimer's disease is progressing according to plan and that the Company has now recruited half of the patients to the study where safety and tolerability is tested. The company expects the study to be fully recruited in 2022.Alzinova's Phase 1b study for the vaccine candidate ALZ-101 against Alzheimer's disease continues according to plan and the study has now been recruited to 50%. Full recruitment is expected to be completed in 2022. The vaccine ALZ-